GR3034535T3 - Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer - Google Patents
Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancerInfo
- Publication number
- GR3034535T3 GR3034535T3 GR20000402225T GR20000402225T GR3034535T3 GR 3034535 T3 GR3034535 T3 GR 3034535T3 GR 20000402225 T GR20000402225 T GR 20000402225T GR 20000402225 T GR20000402225 T GR 20000402225T GR 3034535 T3 GR3034535 T3 GR 3034535T3
- Authority
- GR
- Greece
- Prior art keywords
- antisense oligonucleotides
- cancer
- treatment
- protein kinase
- regulatory subunit
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 title 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RI alpha antisense oligonucleotides and pharmaceutical compositions thereof are disclosed. Methods for treating certain cancers in animals comprising administering to animals an effective amount of an RI alpha antisense oligonucleotide, or a pharmaceutical composition thereof, are also disclosed.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60711390A | 1990-11-02 | 1990-11-02 | |
US68019891A | 1991-04-05 | 1991-04-05 | |
US07/702,163 US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
EP91118628A EP0490077B1 (en) | 1990-11-02 | 1991-10-31 | Antisense oligonucleotides for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3034535T3 true GR3034535T3 (en) | 2001-01-31 |
Family
ID=27416969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR970402319T GR3024673T3 (en) | 1990-11-02 | 1997-09-10 | Antisense oligonucleotides for treatment of cancer |
GR20000402225T GR3034535T3 (en) | 1990-11-02 | 2000-10-02 | Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR970402319T GR3024673T3 (en) | 1990-11-02 | 1997-09-10 | Antisense oligonucleotides for treatment of cancer |
Country Status (9)
Country | Link |
---|---|
US (3) | US5271941A (en) |
EP (3) | EP0785252B1 (en) |
KR (1) | KR0171210B1 (en) |
AT (2) | ATE156517T1 (en) |
CA (2) | CA2054325C (en) |
DE (2) | DE69132299T2 (en) |
DK (2) | DK0785252T3 (en) |
ES (2) | ES2148838T3 (en) |
GR (2) | GR3024673T3 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US6995146B2 (en) * | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
EP0750516A4 (en) | 1993-03-26 | 1998-07-01 | Univ Jefferson | Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides |
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
EP0722342B1 (en) * | 1993-09-20 | 2004-12-29 | The Trustees Of The University Of Pennsylvania | REGULATION OF bcl-2 GENE EXPRESSION |
US5618709A (en) * | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
US5726297A (en) * | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
US5599922A (en) * | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US7074768B2 (en) * | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US20050054600A1 (en) * | 1995-08-17 | 2005-03-10 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
US6624293B1 (en) * | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
AU6328598A (en) * | 1997-03-12 | 1998-09-29 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6312941B1 (en) | 1997-11-26 | 2001-11-06 | The Regents Of The University Of Michigan | Compositions and methods for identifying signaling pathway agonists and antagonists |
WO2000079281A1 (en) * | 1999-06-18 | 2000-12-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US6489356B2 (en) | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
EP2351855A1 (en) | 2000-09-26 | 2011-08-03 | Duke University | RNA aptamers and methods for identifying the same |
EP1326892A2 (en) | 2000-10-12 | 2003-07-16 | University of Rochester | Compositions that inhibit proliferation of cancer cells |
KR100408916B1 (en) * | 2000-11-23 | 2003-12-11 | 주식회사 바이오제니아 | An anticancer drug comprising a mycolactone, an antisense Rb oligonucleotide that decreases human retinoblastoma protein expression and an anticancer drug comprising a mycolactone and the said antisense Rb oligonucleotide |
US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
AU2003209030B2 (en) | 2002-02-06 | 2009-02-05 | Stasys Technologies, Inc. | Anti-infarction molecules |
EP1534729A2 (en) * | 2002-02-26 | 2005-06-01 | University of Utah Research Foundation | Variants of nedd4l associated with hypertension and viral budding |
EP2116604A1 (en) | 2002-08-05 | 2009-11-11 | University of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
AU2003293412A1 (en) * | 2002-12-05 | 2004-06-30 | The Research Foundation Of State University Of Newyork | HIGH EFFICACY ANTISENSE RiAlpha PKA POLY-DNP OLIGORIBONUCLEOTIDES |
US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
US8029815B2 (en) * | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
EP1765065B1 (en) | 2004-05-21 | 2012-06-27 | University of Utah Research Foundation | Methods and compositions related to delivery of chemical compounds to invertebrate embryos |
EP2484780A1 (en) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Methods and materials for determining pain sensibility and predicting and treating related disorders |
EP2535355B1 (en) | 2005-03-23 | 2019-01-02 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
EP2402435A3 (en) | 2005-10-14 | 2012-03-28 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
DK2056845T3 (en) | 2006-08-08 | 2017-11-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | STRUCTURE AND USE OF 5'-PHOSPHATE OLIGONUCLEOTIDES |
EP2560001B1 (en) | 2006-09-21 | 2016-04-13 | University of Rochester | Compositions and methods related to protein displacement therapy for myotonic distrophy |
US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
WO2008073441A2 (en) | 2006-12-11 | 2008-06-19 | University Of Utah Research Foundation | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
EP2030615A3 (en) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
US8501912B2 (en) | 2007-12-03 | 2013-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Filipil compositions and methods for treating cancer |
EP2853897A1 (en) | 2008-05-08 | 2015-04-01 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
JP5689413B2 (en) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 5 'triphosphate oligonucleotide having blunt ends and uses thereof |
WO2010019963A2 (en) * | 2008-08-15 | 2010-02-18 | Georgetown University | Na channels, disease, and related assays and compositions |
EP2370080A1 (en) | 2008-12-02 | 2011-10-05 | University of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
US9970002B2 (en) | 2012-12-12 | 2018-05-15 | Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
WO2015077566A1 (en) | 2013-11-21 | 2015-05-28 | Huang Zhen | Methods for structural determination of selenium derivatized nucleic acid complexes |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
CN107636159B (en) | 2015-02-04 | 2022-06-14 | 百时美施贵宝公司 | Method for selecting therapeutic molecules |
EP3653712B1 (en) * | 2015-02-04 | 2022-11-30 | F. Hoffmann-La Roche AG | Tau antisense oligomers and uses thereof |
SG11201900738YA (en) | 2016-07-28 | 2019-02-27 | Regeneron Pharma | Gpr156 variants and uses thereof |
WO2018026943A1 (en) | 2016-08-03 | 2018-02-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted therapeutics |
JP7458785B2 (en) | 2017-01-23 | 2024-04-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) variants and their uses |
CN110997906B (en) | 2017-06-05 | 2024-05-07 | 雷杰纳荣制药公司 | B4GALT1 variants and uses thereof |
WO2019050899A1 (en) | 2017-09-06 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
AU2018330458A1 (en) | 2017-09-07 | 2020-03-19 | Regeneron Pharmaceuticals, Inc. | Solute Carrier Family 14 Member 1 (SLC14A1) variants and uses thereof |
US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
MX2020003565A (en) | 2017-10-16 | 2020-10-08 | Regeneron Pharma | Cornulin (crnn) variants and uses thereof. |
WO2021003295A1 (en) | 2019-07-02 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Modulators of hsd17b13 and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
NO864301L (en) * | 1986-10-28 | 1988-04-29 | Tore Jahnsen | DNA PROBLEMS FOR HUMAN REGULATORY UNIT OF CAMP-DEPENDED PROTEIN KINASES. |
DE68926455T2 (en) * | 1988-07-05 | 1996-10-31 | Baylor College Medicine | METHOD FOR IDENTIFYING BACTERIA |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
-
1991
- 1991-05-20 US US07/702,163 patent/US5271941A/en not_active Expired - Lifetime
- 1991-10-28 CA CA002054325A patent/CA2054325C/en not_active Expired - Fee Related
- 1991-10-28 CA CA002488792A patent/CA2488792A1/en not_active Abandoned
- 1991-10-31 ES ES97100277T patent/ES2148838T3/en not_active Expired - Lifetime
- 1991-10-31 DK DK97100277T patent/DK0785252T3/en active
- 1991-10-31 AT AT91118628T patent/ATE156517T1/en not_active IP Right Cessation
- 1991-10-31 DK DK91118628.6T patent/DK0490077T3/en active
- 1991-10-31 AT AT97100277T patent/ATE194383T1/en not_active IP Right Cessation
- 1991-10-31 DE DE69132299T patent/DE69132299T2/en not_active Expired - Fee Related
- 1991-10-31 EP EP97100277A patent/EP0785252B1/en not_active Expired - Lifetime
- 1991-10-31 EP EP91118628A patent/EP0490077B1/en not_active Expired - Lifetime
- 1991-10-31 DE DE69127175T patent/DE69127175T2/en not_active Expired - Fee Related
- 1991-10-31 EP EP99119780A patent/EP0972831A1/en not_active Withdrawn
- 1991-10-31 ES ES91118628T patent/ES2104644T3/en not_active Expired - Lifetime
- 1991-11-02 KR KR1019910019468A patent/KR0171210B1/en not_active IP Right Cessation
-
1993
- 1993-05-14 US US08/060,984 patent/US5627158A/en not_active Expired - Fee Related
-
1995
- 1995-02-02 US US08/383,742 patent/US5691317A/en not_active Expired - Fee Related
-
1997
- 1997-09-10 GR GR970402319T patent/GR3024673T3/en unknown
-
2000
- 2000-10-02 GR GR20000402225T patent/GR3034535T3/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5627158A (en) | 1997-05-06 |
EP0490077A1 (en) | 1992-06-17 |
US5271941A (en) | 1993-12-21 |
CA2488792A1 (en) | 1992-05-03 |
KR0171210B1 (en) | 1999-02-01 |
CA2054325C (en) | 2005-03-15 |
ATE156517T1 (en) | 1997-08-15 |
DE69127175D1 (en) | 1997-09-11 |
DE69127175T2 (en) | 1998-03-12 |
EP0785252B1 (en) | 2000-07-05 |
EP0972831A1 (en) | 2000-01-19 |
EP0490077B1 (en) | 1997-08-06 |
ATE194383T1 (en) | 2000-07-15 |
US5691317A (en) | 1997-11-25 |
DK0490077T3 (en) | 1998-01-26 |
DE69132299D1 (en) | 2000-08-10 |
GR3024673T3 (en) | 1997-12-31 |
DE69132299T2 (en) | 2001-02-15 |
EP0785252A1 (en) | 1997-07-23 |
ES2104644T3 (en) | 1997-10-16 |
DK0785252T3 (en) | 2000-10-02 |
ES2148838T3 (en) | 2000-10-16 |
CA2054325A1 (en) | 1992-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3034535T3 (en) | Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer | |
SE9301951D0 (en) | METHODS FOR ADMINISTRATION OF TAXOL | |
IL222002B (en) | Composition of taxane for use in treating cancer, restenosis and retinopathy | |
DE69533112T2 (en) | USE OF FLAVOLIGNANES FOR THE PRODUCTION OF MEDICINES WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, BREAST, EGGS | |
UA39158C2 (en) | derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon | |
NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
IL101145A0 (en) | Pharmaceutical compositions containing synergistic combinations of nucleoside derivatives | |
IL133784A (en) | Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer | |
BR9813318A (en) | Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient | |
IL125776A (en) | Use of a cimicifuga racemosa extract for the manufacture of a drug for treating estrogen-dependent tumors | |
BR0009524A (en) | Use of a compound, and, pharmaceutical or veterinary composition | |
ES2160643T3 (en) | COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF. | |
PL322732A1 (en) | Pharmaceutic agent containing n-chlorophenyl carbaminates and n-chlorophenyl thiocarbaminates for inhibiting development of viruses and carcinoma | |
IL121272A (en) | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia | |
ES2172171T3 (en) | MEDICINAL PRODUCT, CONTAINING YOHIMBINE AND ARGININE, FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS. | |
EP0281070A3 (en) | Pharmaceutical composition for the treatment of cancer | |
HUP0100350A3 (en) | Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use | |
MXPA00010254A (en) | The treatment of sexual dysfunction in certain patient groups. | |
IL118218A (en) | Pharmaceutical compositions containing sarcodictyins | |
PT1076561E (en) | COMBINATION THERAPY FOR THE TREATMENT OF TUMORS | |
ZA837972B (en) | Method of analgesic treatment and pharmaceutical compositions | |
IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ML | Lapse due to non-payment of fees |